Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.
Ivo Carre, PhD
Advertisement
Ivo Carre, PhD, is a senior business analyst at Lifescience Dynamics.
Articles by Ivo Carre, PhD
New data in high-risk MDS, emerging menin inhibitors in AML, and evolving care needs in rare bleeding disorders set the stage for major ASH 2025 discussions.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
5